3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Gynecologic
2
Gastrointestinal
2
Plasma cell
1
Lymphoid
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Advanced Solid Tumors
4
Squamous Cell Carcinoma of Head and Neck
3
Carcinoma, Renal Cell
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Melanoma
2
Esophageal Neoplasms
2
Triple Negative Breast Neoplasms
1
Solid Tumors
1
Solid Tumor, Unspecified, Adult
1
Solid Tumor
1
Pharyngeal Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms
1
Multiple Myeloma
1
Mouth Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Head and Neck Neoplasms
1
Erythrocytosis, Familial, 4
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Interventions
Carboplatin
19
Paclitaxel
18
Fluorouracil
16
Cisplatin
16
pembrolizumab
15
Radiotherapy
14
Oxaliplatin
12
Irinotecan
12
Capecitabine
12
Cyclophosphamide
10
Radiation
8
Leucovorin
8
Docetaxel
8
fludarabine
6
Taxes
6
Gemcitabine
6
Trastuzumab
5
fludarabine phosphate
4
aldesleukin
4
LY6K protein, human
4
Fluorodeoxyglucose F18
4
Erlotinib Hydrochloride
4
Bevacizumab
4
spartalizumab
3
Surgical Procedures, Operative
3
S 1 (combination)
3
Pemetrexed
3
Nivolumab
3
Drug Therapy
3
zimberelimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1
×
Esophageal Neoplasms
×
zimberelimab
×
Clear all
NCT05891171
2026-06-05
ARC-25
Arcus Biosciences, Inc.
Phase 1
Active not recruiting
40 enrolled
NCT04772989
2025-08-28
ARC-12
Arcus Biosciences, Inc.
Phase 1
Completed
94 enrolled